Small molecule regulators of postnatal Nkx2.5 cardiomyoblast proliferation and differentiation

Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Journal of Cellular and Molecular Medicine (Impact Factor: 4.01). 12/2011; 16(5):961-5. DOI: 10.1111/j.1582-4934.2011.01513.x
Source: PubMed


While recent data have supported the capacity for a neonatal heart to undergo cardiomyogenesis, it is unclear whether these new cardiomyocytes arise from an immature cardiomyoblast population or from the division of mature cardiomyocytes. By following the expression of enhanced Green Fluorescent Protein (eGFP) in an Nkx2.5 enhancer-eGFP transgenic mice, we have identified a population of immature cells that can undergo cardiomyogenic as well as smooth muscle cell differentiation in the neonatal heart. Here, we examined growth factors and small molecule regulators that potentially regulate the proliferation and cardiomyogenic versus smooth muscle cell differentiation of neonatal Nkx2.5-GFP (+) cells in vitro. We found that A83-01 (A83), an inhibitor of TGF-βRI, was able to induce an expansion of neonatal Nkx2.5-eGFP (+) cells. In addition, the ability of A83 to expand eGFP (+) cells in culture was dependent on signalling from the mitogen-activated protein kinase kinase (MEK) as treatment with a MEK inhibitor, PD0325901, abolished this effect. On the other hand, activation of neonatal Nkx2.5-eGFP (+) cells with TGF-β1, but not activin A nor BMP2, led to smooth muscle cell differentiation, an effect that can be reversed by treatment with A83. In summary, small molecule inhibition of TGF-β signalling may be a promising strategy to induce the expansion of a rare population of postnatal cardiomyoblasts.

Download full-text


Available from: Sean M Wu
  • Source
    • "Conversely, a recent report shows that left ventricular tissue from fetal HLHS patients, which experiences decreased stretch, has increased expression and activation of Tgf-β1 [16]. Indeed, data from stem cell experiment provide evidence that activated Tgf-β signaling inhibits cardiomyogenesis [22] [23] [24]. Furthermore, data from cultured neonatal rat cardiomyocytes suggest that Tgf-β signaling inhibits cardiomyocyte proliferation in vitro [25] [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Perturbed biomechanical stimuli are thought to be critical for the pathogenesis of a number of congenital heart defects, including Hypoplastic Left Heart Syndrome (HLHS). While embryonic cardiomyocytes experience biomechanical stretch every heart beat, their molecular responses to biomechanical stimuli during heart development are poorly understood. We hypothesized that biomechanical stimuli activate specific signaling pathways that impact proliferation, gene expression and myocyte contraction. The objective of this study was to expose embryonic mouse cardiomyocytes (EMCM) to cyclic stretch and examine key molecular and phenotypic responses. Analysis of RNA-Sequencing data demonstrated that gene ontology groups associated with myofibril and cardiac development were significantly modulated. Stretch increased EMCM proliferation, size, cardiac gene expression, and myofibril protein levels. Stretch also repressed several components belonging to the Transforming Growth Factor-β (Tgf-β) signaling pathway. EMCMs undergoing cyclic stretch had decreased Tgf-β expression, protein levels, and signaling. Furthermore, treatment of EMCMs with a Tgf-β inhibitor resulted in increased EMCM size. Functionally, Tgf-β signaling repressed EMCM proliferation and contractile function, as assayed via dynamic monolayer force microscopy (DMFM). Taken together, these data support the hypothesis that biomechanical stimuli play a vital role in normal cardiac development and for cardiac pathology, including HLHS. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Full-text · Article · Nov 2014 · Journal of Molecular and Cellular Cardiology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Muscle diseases are major health concerns. For example, ischemic heart disease is the third most common cause of death. Cell therapy is an attractive approach for treating muscle diseases, although this is hampered by the need to generate large numbers of functional muscle cells. Small molecules have become established as attractive tools for modulating cell behavior and, in this review, we discuss the recent, rapid research advances made in the development of small molecule methods to facilitate the production of functional cardiac, skeletal, and smooth muscle cells. We also describe how new developments in small molecule strategies for muscle disease aim to induce repair and remodelling of the damaged tissues in situ. Recent progress has been made in developing small molecule cocktails that induce skeletal muscle regeneration, and these are discussed in a broader context, because a similar phenomenon occurs in the early stages of salamander appendage regeneration. Although formidable technical hurdles still remain, these new advances in small molecule-based methodologies should provide hope that cell therapies for patients suffering from muscle disease can be developed in the near future.
    No preview · Article · Oct 2012 · ACS Chemical Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The concept of the heart as a terminally differentiated organ incapable of replacing damaged myocytes has been at the center of cardiovascular research and therapeutic development for the last 50 years. The progressive decline in myocyte number as a function of age and the formation of scarred tissue following myocardial infarction have been interpreted as irrefutable proofs of the postmitotic characteristic of the heart. Emerging evidence supports a more dynamic view of the heart, in which cell death and renewal are vital components of the remodeling process that governs cardiac homeostasis, aging, and disease. In a recent study, myocyte regeneration in the physiologically aging heart was found to occur at previously unexpected levels. From 20 to 100 years of age, the myocyte compartment is replaced completely 15 times in women and 11 times in men, and essentially none of the myocytes present at birth is preserved in the young adult, middle-aged, and senescent heart. The identification of dividing myocytes raises the important question concerning the origin of the newly formed cells. In vitro and in vivo findings strongly suggest that replicating myocytes correspond to transit-amplifying cells derived from the lineage determination of primitive cells, supporting the notion that cardiomyogenesis is controlled by activation and differentiation of stem cells. Investigators in several laboratories concur with the notion that the myocardium is an organ permissive for tissue regeneration mediated by exogenous and/or endogenous progenitors. In this chapter, we will focus on the cell classes that are currently employed in clinical studies for the treatment of cardiac diseases. © 2013 Springer Science+Business Media New York. All rights reserved.
    No preview · Article · Jun 2013
Show more